Study details
Enrolling now
64Cu-LNTH-1363S Trial
Lantheus Medical Imaging
NCT IDNCT06298916ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
26
Study length
about 8 months
Ages
15+
Locations
5 sites in CA, MI, OH
About this study
This trial is testing a new treatment called 64Cu-LNTH-1363S in people with sarcoma or gastrointestinal tract cancer. The goal is to see if this treatment is safe and effective, determine the right dose for imaging, and compare its use to another imaging technique.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 64Cu-LNTH-1363S
PhasePhase 1/Phase 2
Primary goalPrimary Part 1 - Optimal dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Primary Part 1 - Optimal dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S
Secondary: Secondary Parts 1 and 2 Safety and Tolerability
Body systems
Oncology